|High / Low range:||0.0167|
ESPERITE (ESP) resumes negotiations regarding proposed sale of stem cell banking business to PBKM
Amsterdam, The Netherlands – 13 June
Esperite N.V. (Euronext: ESP, “Esperite”) announces today
that it has resumed negotiations with Polski Bank
Komórek Macierzystych S.A. (WSE: PBKM, “PBKM”) regarding the
proposed sale of certain assets and liabilities related to
Cryo-Save’s stem cell banking business (the Proposed Sale).
The negotiations were resumed by Esperite after receiving an
expression of renewed interest by PBKM, as announced today by
PBKM. As of today, the parties have not yet reached agreement
on the terms of the Proposed Sale.
As disclosed previously, the MoU regarding the Proposed Sale, including the exclusivity granted to PBKM, was terminated on 28 May 2019.
ESPERITE group, listed at Euronext Amsterdam and Paris, is a
leading international company in regenerative and precision
medicine founded in 2000.
To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - firstname.lastname@example.org.
This press release contains inside information as referred to in article 7 paragraph 1 of Regulation (EU) 596/2014 (Market Abuse Regulation).
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.